Yvonne Kahlert

University Hospital Cologne — Germany

Medicine · Health Sciences

20h-index3.6kcitations92works10.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(82), Cancer, Hypoxia, and Metabolism(27), Neuroendocrine Tumor Research Advances(6), Telomeres, Telomerase, and Senescence(6), Lung Cancer Research Studies(6)

Publications90 total

<i>TERT</i> Expression and Clinical Outcome in Pulmonary Carcinoids
Journal of Clinical Oncology·2024· 10 citedOpen Access
Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Table 6A from High &lt;i&gt;ALK&lt;/i&gt; Receptor Tyrosine Kinase Expression Supersedes &lt;i&gt;ALK&lt;/i&gt; Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Data from Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome
2023Open Access
Supplementary Table 6C from High &lt;i&gt;ALK&lt;/i&gt; Receptor Tyrosine Kinase Expression Supersedes &lt;i&gt;ALK&lt;/i&gt; Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Supplementary Table 4 from High &lt;i&gt;ALK&lt;/i&gt; Receptor Tyrosine Kinase Expression Supersedes &lt;i&gt;ALK&lt;/i&gt; Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Supplementary Data from Subclassification and Individual Survival Time Prediction from Gene Expression Data of Neuroblastoma Patients by Using CASPAR
2023Open Access
Supplementary Table 6B from High &lt;i&gt;ALK&lt;/i&gt; Receptor Tyrosine Kinase Expression Supersedes &lt;i&gt;ALK&lt;/i&gt; Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Supplementary Table 5B from High &lt;i&gt;ALK&lt;/i&gt; Receptor Tyrosine Kinase Expression Supersedes &lt;i&gt;ALK&lt;/i&gt; Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Supplementary Table 3 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Table 1 from Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome
2023Open Access
Legends to Supplementaries from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Data from Subclassification and Individual Survival Time Prediction from Gene Expression Data of Neuroblastoma Patients by Using CASPAR
2023Open Access
Supplementary Table 3 from High &lt;i&gt;ALK&lt;/i&gt; Receptor Tyrosine Kinase Expression Supersedes &lt;i&gt;ALK&lt;/i&gt; Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Supplementary Table 4 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Legends to Supplementaries from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Table 3 from High &lt;i&gt;ALK&lt;/i&gt; Receptor Tyrosine Kinase Expression Supersedes &lt;i&gt;ALK&lt;/i&gt; Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Data from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Data from High &lt;i&gt;ALK&lt;/i&gt; Receptor Tyrosine Kinase Expression Supersedes &lt;i&gt;ALK&lt;/i&gt; Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Frank Berthold(41), Barbara Hero(39), Frank Westermann(34), Benedikt Brors(31), Matthias Fischer(27), André Oberthuer(27), Jessica Theißen(26), Frank Speleman(22), Jo Vandesompele(21), Sandra Ackermann(19), Thorsten Simon(18), Matthias Fischer(18), Roland Eils(16), Angelika Eggert(14), Alexander Schramm(14), Johannes H. Schulte(14), Anne Engesser(13), Dilafruz Juraeva(13), Ruth Volland(12), Katleen De Preter(12)